Protocol Ledger

Clinical Cooperative Network · Consolidated Sponsor Hub

European Organisation for Research and Treatment of Cancer - EORTC: Clinical Trials & FDA Approval Profile

European Organisation for Research and Treatment of Cancer - EORTC (Global / Institutional) sponsors 42 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 21 active protocols (10 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)42.9%
Median Closed Enrollment vs National (145 pts)24 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for European Organisation for Research and Treatment of Cancer - EORTC
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)42
Active Pipeline (Recruiting Now)21 (10)
Completed vs Stopped Early3 / 18 (42.9%)
Median Closed Actual Enrollment24 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With European Organisation for Research and Treatment of Cancer - EORTC
Hospital Research SiteLocationShared Protocols
Hospital Universitario 12 de OctubreMadrid18
Gustave RoussyVillejuif, Île-de-France Region9
Erasmus MCRotterdam9

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by European Organisation for Research and Treatment of Cancer - EORTC
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04031677Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaPhase IIIRECRUITING
NCT06246149Adjuvant Tebentafusp in High Risk Ocular MelanomaPhase IIIRECRUITING
NCT05815927Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck CancerPhase IIIRECRUITING
NCT05512364Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)Phase IIIRECRUITING
NCT06809322Vorasidenib Maintenance for IDH Mutant AstrocytomaPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the European Organisation for Research and Treatment of Cancer - EORTC Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI